



Acarix appoints industry veteran Fred Colen as acting CEO during temporary medical leave of CEO Helen Ljungdahl Round

Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces that CEO Helen Ljungdahl Round will be taking a temporary medical leave of absence to address a treatable form of cancer. Her expected duration of absence is approximately six months. The Board has with immediate effect appointed Fred Colen as Acting CEO during Helen's absence.

Fred Colen has a 40-year career in the cardiovascular field including leading positions as CEO of St. Jude Medical in Sweden, Chief Technology Officer (CTO) of Boston Scientific, President of Boston Scientific's Cardiac Rhythm Management Group (\$2.3 billion revenue business unit with 14,000 employees), Board Member of Mölnlycke Healthcare and numerous CEO and Board roles in smaller ventures. In his last position as CEO and President of Neovasc Inc, Fred was able to raise 100 million USD in capital and successfully lead the company through an acquisition by Shockwave Medical, which closed in April 2023. Fred is currently Chairman of the Board of Xeltis AG and Member of the Board of Onward, a Euronext public company.

Fred was born in 1952, has an MSc in Electrical Engineering with specialization in Medical Technology, from the University of Aachen, and is a citizen of the Netherlands but permanently resides in the USA.

"The Board is very pleased to have been able to attract Fred Colen on a short notice as acting CEO of Acarix while Helen is off on temporary leave. Helen is in good medical hands, and we wish her a rapid recovery. Fred's mission is to continue to execute on Senzimes' strategic plan with his extensive C-level operating experience and a global network from running both early stage and multi-billion-dollar global cardiac medical device businesses", comments Philip Siberg, Chairman of the Board of Acarix AB.

"I am very excited to help bring Acarix's portfolio of sophisticated diagnostic tools further into the market and to contribute to its success. Helen and her team have done an impressive job in the early commercialization, and I believe I can contribute by leading the team to further penetrate the US market in particular and to continue to make progress with respect to reimbursement", comments Fred Colen, new Acting CEO of Acarix AB.

Furthermore, CFO Christian Lindholm has been appointed Executive Vice President with signatory rights to maintain efficient operations in Sweden and Denmark.

For more information contact:

Philip Siberg, Chairman of the Board, phone +46 707 906734, email philip.siberg@acarix.com

Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com



About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of coronary artery disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. The CADScor System has been used on more than 29,000 patients and is recommended as a first-line diagnostic aid as outlined in the clinical workflow developed in collaboration with the American College of Cardiology (ACC). Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Erik Penser Bank AB (+46 8 463 83 00, certifiedadviser@penser.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com.

This information is information that Acarix is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-10-02 19:43 CEST.

Attachments

[Acarix appoints industry veteran Fred Colen as acting CEO during temporary medical leave of CEO Helen Ljungdahl Round](#)